Previous Close | 1.0100 |
Open | 0.9800 |
Bid | 0.8000 x 800 |
Ask | 0.0000 x 1000 |
Day's Range | 0.9200 - 0.9996 |
52 Week Range | 0.7400 - 9.3700 |
Volume | |
Avg. Volume | 510,945 |
Market Cap | 40.201M |
Beta (5Y Monthly) | 1.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AVRO
CAMBRIDGE, Mass., May 18, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the "Disease models and Clinical Applications: Musculo-skeletal Diseases" poster session at the American Society of Gene
CAMBRIDGE, Mass., May 17, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported new interim data, including on new visual motor integration, motor coordination and visual perception measures, from a collaborator-sponsored, ongoing Phase 1/2 gene therapy clinical triali of AVR-RD-04, an investigational gene therapy for cystinosis, at the 25th Annual Meeting of American Society for G
CAMBRIDGE, Mass., May 16, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced members of its senior management team will be presenting virtually at the H.C. Wainwright Global Investment Conference, May 23-25, 2022.